Who are Aldeyra Therapeutics, Inc.'s major customers?

Aldeyra Therapeutics, Inc. (ALDX) key customers include: AbbVie Inc., AbbVie Inc., FACEBOOK-IRELAND-LIMITED. View the full customer network at chainsifter.com/chain/ALDX.

What sector is Aldeyra Therapeutics, Inc. in?

Aldeyra Therapeutics, Inc. (ALDX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Aldeyra Therapeutics, Inc. (ALDX): 6 Verified Supply Chain Relationships

0Suppliers

3Customers

3Debt Items

13Related Chains

Source-Backed Evidence Depth

Aldeyra Therapeutics, Inc. (ALDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

7Total relationships

2Distinct source URLs

6High confidence

0.860Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Aldeyra Therapeutics, Inc. Suppliers

No suppliers on recordAldeyra Therapeutics, Inc. does not appear to disclose named supplier relationships in its verified regulatory filings, or upstream suppliers have not yet been identified. Our system processes new filings continuously.

Aldeyra Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
ABBV	AbbVie Inc.	90%	Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap.
ABBV	AbbVie Inc.	90%	Reciprocal relationship from ABBV graph: Reciprocal relationship from ALDX graph: Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap.
FACEBOOK-IRELAND-LIMITED	FACEBOOK-IRELAND-LIMITED	62%	the EU. Transfer mechanisms have also been subject to various legal challenges. In particular, on July 16, 2020, the Court of Justice of the European Union, in the case of Data Protection Commissione…

Aldeyra Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ALDX-DEBT-7670	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2014-12-31.
ALDX-DEBT-7669	Warrants outstanding: 211528	90%	xbrl warrant detail from xbrl 2018-12-31.
ALDX-DEBT	Debt stack $15.3M	90%	Market cache reports total debt of $15.3M.

Aldeyra Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Aldeyra Therapeutics, Inc..

Aldeyra Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
ALDX-OWNER-KNOLL-CAPITAL-MANAGEMENT-LLC	Knoll Capital Management, LLC	90%	13F overlay lists Knoll Capital Management, LLC as top holder; 125 tracked holders.

Aldeyra Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ABBV	AbbVie Inc.	100.00	1	['customer']
ABBVIE	ABBVIE	60.75	1	['receiving']
RGNX	REGENXBIO Inc.	50.00	2
ESGL	ESGL Holdings Limited	50.00	2
SION	Sionna Therapeutics, Inc.	50.00	2
IRON	Disc Medicine, Inc.	50.00	2
IRWD	Ironwood Pharmaceuticals, Inc.	50.00	2
JNJ	Johnson & Johnson	50.00	2
LCTX	Lineage Cell Therapeutics, Inc.	50.00	2
PHVS	Pharvaris N.V.	50.00	2
XLO	Xilio Therapeutics, Inc.	50.00	2
ARGX	argenx SE	50.00	2
CTMX	CytomX Therapeutics, Inc.	50.00	2

Aldeyra Therapeutics, Inc. Supply Chain